Atopic dermatitis (AD) is a common, chronic, recurrent, immune-mediated inflammatory skin disease. Targeted treatment options remain limited. Tralokinumab (Adtralza®) is a promising, new systemic therapy that inhibits interleukin-13. It was recently approved by Health Canada and the US FDA for the treatment of moderate-to-severe AD in adults and may be used alone or with topical corticosteroids. Herein, we review the efficacy and safety of tralokinumab in adults, as demonstrated in clinical trials.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
atopic dermatitis
8
tralokinumab moderate-to-severe
4
moderate-to-severe atopic
4
dermatitis adults
4
adults atopic
4
dermatitis common
4
common chronic
4
chronic recurrent
4
recurrent immune-mediated
4
immune-mediated inflammatory
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!